Literature DB >> 23574431

Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality.

Gerry Oster1, Ariel Berger, John Edelsberg, David J Weber.   

Abstract

OBJECTIVES: To identify risk factors for initial treatment failure in patients with community-acquired pneumonia (CAP) in non-intensive care unit (non-ICU) settings, and to characterize the association between initial treatment failure and length of stay, total hospital charges, and mortality.
METHODS: Retrospective cohort study. Using data from >100 US hospitals, this study identified all adults (age ≥18 years) hospitalized for pneumonia between January 1, 2000 and June 30, 2009 who began antibiotic therapy within 24 h of admission and were treated for at least 48 h if alive; patients admitted to intensive care within the first 24 h in hospital were excluded. Initial therapy was defined as all parenteral antibiotics administered within the first 24 h in hospital. Treatment failure was assessed based on subsequent receipt of new antibiotic(s), excluding agents of similar/narrower spectrum and those begun at discharge. Multivariate logistic regression was used to identify risk factors for treatment failure, and multivariate linear and logistic regression to compare length of stay, total hospital charges, and in-hospital mortality between patients experiencing initial treatment failure and those who did not.
RESULTS: Among 32,324 patients with non-ICU CAP, 4695 (14.6%) experienced initial treatment failure, most often within 72 h of hospital admission. Significant predictors of initial treatment failure included malnourishment (OR = 1.87; 95% CI = 1.60-2.18), receipt of vasoactive medications within 24 h of admission (1.51 [1.17-1.94]), and renal failure (1.45 [1.32-1.59]). Treatment failure was associated with higher case fatality (8.5% vs 3.3%), longer hospital stays (mean [SD] = 10.1 [8.1] days vs 4.9 [3.3] days), and higher total hospital charges ($37,602 [$71,876] vs $14,371 [$21,633]) (all comparisons, p < 0.01). Study limitations include possible inclusion of patients with healthcare-associated pneumonia (HCAP) in the study sample, our focus on the 40 most commonly used antibiotic regimens, and indirect measurement of treatment failure.
CONCLUSIONS: Approximately one in seven non-ICU CAP patients experience failure of initial antibiotic therapy. Risk of failure is higher for patients with significant comorbidities and/or severe infections. Non-ICU patients who experience initial treatment failure have significantly longer hospital stays, higher total hospital charges, and higher rates of mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574431     DOI: 10.3111/13696998.2013.794805

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  10 in total

1.  Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Authors:  Susanne Paukner; Steven P Gelone; S J Ryan Arends; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Association of Intensive Care Unit Admission With Mortality Among Older Patients With Pneumonia.

Authors:  Thomas S Valley; Michael W Sjoding; Andrew M Ryan; Theodore J Iwashyna; Colin R Cooke
Journal:  JAMA       Date:  2015 Sep 22-29       Impact factor: 56.272

3.  An audit and feedback intervention study increased adherence to antibiotic prescribing guidelines at a Norwegian hospital.

Authors:  June Utnes Høgli; Beate Hennie Garcia; Frode Skjold; Vegard Skogen; Lars Småbrekke
Journal:  BMC Infect Dis       Date:  2016-02-27       Impact factor: 3.090

Review 4.  Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

Authors:  Bin Cao; Yi Huang; Dan-Yang She; Qi-Jian Cheng; Hong Fan; Xin-Lun Tian; Jin-Fu Xu; Jing Zhang; Yu Chen; Ning Shen; Hui Wang; Mei Jiang; Xiang-Yan Zhang; Yi Shi; Bei He; Li-Xian He; You-Ning Liu; Jie-Ming Qu
Journal:  Clin Respir J       Date:  2017-09-26       Impact factor: 2.570

Review 5.  Severe acute respiratory distress syndrome (ARDS) induced by human adenovirus B21: Report on 2 cases and literature review.

Authors:  Carmen Andrea Pfortmueller; Maria Teresa Barbani; Joerg Christian Schefold; Elias Hage; Albert Heim; Stefan Zimmerli
Journal:  J Crit Care       Date:  2019-02-13       Impact factor: 3.425

6.  Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model.

Authors:  Erin B Brazel; Aimee Tan; Stephanie L Neville; Amy R Iverson; Saumya R Udagedara; Bliss A Cunningham; Mwilye Sikanyika; David M P De Oliveira; Bernhard Keller; Lisa Bohlmann; Ibrahim M El-Deeb; Katherine Ganio; Bart A Eijkelkamp; Alastair G McEwan; Mark von Itzstein; Megan J Maher; Mark J Walker; Jason W Rosch; Christopher A McDevitt
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.995

7.  Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department.

Authors:  Scott T Micek; Adam Lang; Brian M Fuller; Nicholas B Hampton; Marin H Kollef
Journal:  BMC Infect Dis       Date:  2014-02-05       Impact factor: 3.090

Review 8.  Community-acquired bacterial pneumonia in adults: An update.

Authors:  Vandana Kalwaje Eshwara; Chiranjay Mukhopadhyay; Jordi Rello
Journal:  Indian J Med Res       Date:  2020-04       Impact factor: 2.375

Review 9.  Hospitalized Patients with Acute Pneumonia.

Authors:  Shaheen Najafi; Christian Sandrock
Journal:  Hosp Med Clin       Date:  2017-09-15

Review 10.  Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies.

Authors:  Sandeep Nayar; Ashfaq Hasan; Pradyut Waghray; Srinivasan Ramananthan; Jaishid Ahdal; Rishi Jain
Journal:  Lung India       Date:  2019 Nov-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.